AD Pipeline Watch: Apogee’s APG777 Continues to Shine in Phase 1 AD Study
Apogee Therapeutics, Inc. APG777 continues to show promise in atopic dermatitis (AD), according to early data. APG777 is a novel half-life extended anti-interleukin (IL)-13 antibody under development for the treatment for AD and other inflammatory diseases. Pharmacokinetic data up to 9 months show a half-life of approximately 75 days, approximately three to five times that […]